Anti-TNF monoclonal antibodies have been used for the treatment of rheumatoid arthritis (RA) and inflammatory bowel disease, and anti-IL-17 antibodies have also shown some efficacy for the treatment of RA (107). Here, IL17A is linked to rheumatoid arthritis.